BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27287845)

  • 1. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
    Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27287845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers.
    Pissa M; Lapins J; Sköldmark C; Helgadottir H
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):284-292. PubMed ID: 36156317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
    Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
    Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
    De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
    Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Familial Melanoma in Valencia, Spain, Based on the Presence of CDKN2A Mutations and MC1R Variants.
    Huerta C; Garcia-Casado Z; Bañuls J; Moragon M; Oliver V; Unamuno B; Requena C; Kumar R; Nagore E
    Acta Derm Venereol; 2018 Apr; 98(5):512-516. PubMed ID: 29405243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
    Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
    Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
    Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature.
    Sargen MR; Merrill SL; Chu EY; Nathanson KL
    Br J Dermatol; 2016 Oct; 175(4):785-9. PubMed ID: 26876133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
    Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
    Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
    Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
    Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
    Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
    Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
    Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Increased knowledge on familial melanoma and the underlying genetics].
    Helgadottir H; Nielsen K; Höiom V
    Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.
    Helgadottir H; Höiom V; Jönsson G; Tuominen R; Ingvar C; Borg A; Olsson H; Hansson J
    J Med Genet; 2014 Aug; 51(8):545-52. PubMed ID: 24935963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
    Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
    Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.